Small study tackles nasty side effect of lung drug
NCT ID NCT06200714
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study followed 18 people in Spain with idiopathic pulmonary fibrosis (IPF) or other progressive lung scarring who were taking nintedanib (OFEV) and had developed diarrhea. The goal was to see if the diarrhea could be controlled after 12 weeks while staying on the full dose. Researchers tracked how many patients had fewer than 3 loose stools per day. It is an observational study, meaning no new treatment was tested—just real-world data collection.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- nintedanib (OFEV)
- What this could lead to
- If successful, this could help doctors manage a common side effect of nintedanib, allowing patients to stay on their lung fibrosis treatment with less discomfort.
- What could go wrong
- This is a very small observational study (18 people) with no control group, so results may not apply to everyone. It only looks at diarrhea control, not whether the drug works for the lung disease.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for DIARRHOEA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Hospital Clínic i Provincial de Barcelona
Barcelona, 08036, Spain
-
Hospital Clínico San Carlos
Madrid, 28040, Spain
-
Hospital Clínico Universitario de Valencia
Valencia, 46010, Spain
-
Hospital Universitari Germans Trias i Pujol
Barcelona, 08916, Spain
-
Hospital Universitario Virgen de las Nieves
Granada, 18014, Spain
-
Hospital Universitario de Cruces
Bizkaia, 48903, Spain
-
Hospital de La Princesa
Madrid, 28006, Spain
-
Hospital Álvaro Cunqueiro
Pontevedra, 36312, Spain
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a new pill slow lung scarring in IPF?
- Beyond the lungs: the hidden emotional toll of IPF medications
- Can umbilical cord stem cells ease a scarring lung disease?
- Spotting hidden blood clots in scarred lungs: a study hunts for clues
- What makes someone stop a lung fibrosis drug? a study asks patients directly
- A smarter way to track lung disease? new platform aims to personalize COPD and IPF care